The neuroprotective agent riluzole activates the two P domain K+ channels TREK-1 and TRAAK

Molecular Pharmacology

Volumn 57, Issue 5, 2000, Pages 906-912

  Duprat, Fabrice ^a   Lesage, Florian ^a   Patel, Amanda J ^a   Fink, Michel ^a   Romey, Georges ^a   Lazdunski, Michel ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POTASSIUM CHANNEL; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; BRAIN ISCHEMIA; BRAIN PROTECTION; DRUG EFFECT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; COS CELLS; CYCLIC AMP; NEUROPROTECTIVE AGENTS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; PROTEIN STRUCTURE, TERTIARY; RILUZOLE; TRANSFECTION;

EID: 0034015102     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. + channels. Science 247:852-854.
2. Barneoud P, Mazadier M, Miquet JM, Parmentier S, Dubedat P, Doble A and Boireau A (1996) Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74:971-983.
3. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM and Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: A pilot study. Eur J Pharmacol 284:299-307.
4. Benoit E and Escande D (1991) Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre. Pflügers Arch. 419:603-609.
5. Bensimon G, Lacomblez L and Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330:585-591.
6. Boireau A, Dubedat P, Bordier F, Peny C, Miquet J-M, Durand G, Meunier M and Doble A (1994) Riluzole and experimental parkinsonism: Partial antagonism of MPTP-induced increase in striatal extracellular dopamine in rats in vivo. NeuroReport 5:2157-2160.
7. Bryson HM, Fulton B and Benfield P (1996) Riluzole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drug Eval 52:549-563.
8. Cheramy A, Barbeiro L, Godeheu G and Glowinski J (1992) Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147:209-212.
9. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47 (Suppl 4):5S233-S241.
10. + channel to sense external pH variations near physiological pH. EMBO J. 16:5464-5471.
11. Ettaiche M, Fillacier K, Widmann C, Heurteaux C and Lazdunski M (1999) Riluzole improves functional recovery following ischemia in the rat retina. Invest Ophthalmol Visual Sci 40:729-736.
12. + channel. EMBO J. 15:6854-6862.
13. + channel activated by arachidonic acid and polyunsaturated fatty acids. EMBO J. 17:3297-3308.
14. + channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloid beta-protein precursor genes and neuronal death in rat hippocampus. Proc Natl Acad Sci USA 90:9431-9435.
15. Heurteaux C, Lauritzen I, Widmann C and Lazdunski M (1994) Glutamate-induced overexpression of NMDA receptor messenger RNAs and protein triggered by activation of AMPA/kainate receptors in rat hippocampus following forebrain ischemia. Brain Res 659:67-74.
16. Hille B (1992) Ionic Channels in Excitable Membranes, Sinauer Associates Inc., Sunderland, Massachusetts.
17. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G and Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344.
18. Lang-Lazdunski L, Vaillant N, Widmann C, Heurteaux C and Lazdunski M (1999) Riluzole prevents ischemic spinal cord injury caused by aortic cross-clamping. J Thorac Cardiovasc Surg 117:881-889.
19. + channel with a novel structure. EMBO J 15:1004-1011.
20. Lesage F and Lazdunski M (1999) Potassium channels with two pore domains, in Handbook of Experimental Pharmacology. Pharmacology of ionic channel function: activators and inhibitors (Endo M, Mishina M and Y Kurachi eds) Springer-Verlag, Berlin.
21. MacIver MB, Amagasu SM, Mikulec AA and Monroe FA (1996) Riluzole Anesthesia: Use-dependent block of presynaptic glutamate fibers. Anesthesiology 85:626-634.
22. + channel. J Biol Chem 274:1381-1387.
23. Malgouris C, Bardot F, Daniel M, Pellis F, Rataud J, Uzan A, Blanchard JC and Laduron PM (1989) Riluzole, a novel antiglutamate, prevent memory loss and hippocampal neuronal damage in ischemic gerbils. J Neurosci 9:3720-3727.
24. Mantz J, Cheramy A, Thierry AM, Glowinski J and Desmonts JM (1992) Anesthetic properties of riluzole (54274 RP), a new inhibitor of glutamate neurotransmission. Anesthesiology 76:844-848.
25. Martin D, Thompson MA and Nadler JV (1993) The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol 260:473-476.
26. Mary V, Wahl F and Stutzmann JM (1995) Effect of riluzole on quinolinate-induced neuronal damage in rats: Comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 1:92-96.
27. Nicholson CD, Jackman SA and Wilke R (1989) The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site. Br J Pharmacol 97:889-897.
28. + channels. Nature Neurosci 2:422-426.
29. + channel. EMBO J 17:4283-4290.
30. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM and Stutzmann JM (1992) Neuroprotective actions of Riluzole in rodent models of global and focal cerebral ischemia. Neurosci Lett 140:225-230.
31. + channel openers: Pharmacological and clinical aspects. Fundam Clin Pharmacol 6:279-293.
32. + channel from human kidney. J Biol Chem 273:30863-30869.
33. Reyes R, Lauritzen I, Lesage F, Ettaiche M, Fosset M and Lazdunski M (2000) Immunolocalization of the arachidonic-acid and mechano-sensitive baseline TRAAK potassium channel in the nervous system. Neuroscience 95:893-901.
34. Romettino S, Lazdunski M and Gottesmann C (1991) Anticonvulsant and sleep-waking influences of riluzole in a rat model of absence epilepsy. Eur J Pharmacol 199:371-373.
35. Springer JE, Azbill RD, Kennedy SE, George J and Geddes JW (1997) Rapid calpain I activation and cytoskeletal protein degradation following traumatic spinal cord injury: Attenuation with riluzole pretreatment. J Neurochem 69:1592-1600.
36. Stutzmann J-M, Böhme GA, Gandolfo G, Gottesmann C, Lafforgue J, Blanchard J-C, Laduron PM and Lazdunski M (1991) Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol 193:223-229.
37. Stutzmann J-M, Pratt J, Boraud T and Gross C (1996) The effect of riluzole on post traumatic spinal cord injury in the rat. NeuroReport 7:387-392.
38. Torphy TJ, Zhou HL and Cieslinski LB (1992) Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J Pharmacol Exp Ther 263:1195-1205.
39. Wahl F, Allix M, Plotkine M and Boulu RG (1993) Effect of riluzole on focal cerebral ischemia in rats. Eur J Pharmacol 230:209-214.
40. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM and Evans DB (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 35:787-800.
41. Wokke J (1996) Riluzole. Lancet 348:795-809.